|
|
Profile
|
Delegates :
Masayuki Fukumura |
|
Incorporated :
May 30 , 2008 |
Paid in Capital :
27 Million yen |
Employees :
2 人 |
Address :
Mie-gun, Komono-cho, Komono, 1325 MIE
〒5101233
|
TEL/FAX :
+81-59-392-7333 / +81-59-392-7333 |
URL：
http://www.biocomo.jp/?page_id=276 |
Attachment :
|
Mission/Background :
BioComo Inc. focuses on the research & development of a novel vaccine technology named 5’-PPP-RIV that prevents pathogenic infections and malignant tumors using respiratory infections human parainfluenza type 2 vector (hPIV2) developed in a Mie University graduate school medicine. |
|
Technology & Business
|
What is 5’-PPP-RIV technology?
5'-PPP-RIV is an unprecedented system for delivering antigens that can efficiently promote Th-1 immune response without adjuvants while inactivated paramyxovirus vector.
Strong point of 5’-PPP-RIV
5’-PPP-RIV is a virus-like vesicle based on hPIV2 that can be processed by professional APCs and promote Th-1 biased immune response in a highly effective and efficient way.
As it can incorporate plural peptide antigens and efficiently induce a protective immune response without adjuvants, 5’-PPP-RIV is a flexible new tool for developing novel prophylactic and therapeutic vaccines for a variety of diseases.
Business
・Providing of vaccine platform technology containing peptide antigens
・Development of prophylactic and therapeutic vaccines against infectious diseases and malignant tumors
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
5’-PPP-RIV vaccine platforms
|
Discovery
|
a virus-like vesicle, named as 5’-PPP-IV, capable of incorporation of plural peptide antigens
|
a tie up, joint development
|
5’-PPP-RIV with a universal flu antigen, or infectious disease related antigens
|
Discovery
|
Prophylactic vaccine efficacy in animal testing
|
a tie up, joint development
|
5’-PPP-RIV with tumor associated antigens (TAAs)
|
Discovery
|
Inhibitory effect on growth of tumor cells in animal testing
|
a tie up, joint development
|
|
|
|
|
|
|
|
|
|
Highlights
|
We have applied for the patent and published the paper on the novel vaccine technology and started the establishment of the partnership with some companies to promote the development of vaccines. In addition, we have succeeded in the development of a high performance model of 5’-PPP-RIV that much more and more plural of antigen peptides can be introduced to.
|
|
Alliance strategy
|
We hoped to work together or tie up with a pharmaceutical company or a biotech that is interested in novel vaccine technology in the areas of infectious diseases or malignant tumors.
|
|
|